Combretastatin analogs

The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.

ABSTRACT

The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.

CLAIMS

1. A method of inhibiting tubulin polymerization in a subject, the method comprising administering to the subject a compound comprising Formula (V) in combination with at least one pharmaceutically acceptable excipient:  wherein: G is chosen from Q is a quinolinyl moiety; R1, R2, R3, R4, R7, R8, R9, R10, and R11 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, alkylalkylamino, amidine, amino, carboxyl, cyano, ester, halogen, hydroxyl, and nitro; R5 is hydrogen and R6 is cyano; X and Y are independently chosen from O, CR12, CR12R13, S, SR14, N, or NR15, with the proviso that when X is N and Y is S or when Y is N and X is S, at least one of R7, R8, R9, R10, and R11 is not a hydrogen; R12, R13, R14, and R15 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, alkylalkylamino, amidine, amino, carboxyl, cyano, ester, halogen, hydroxyl, and nitro; and  are independently a single bond that is present or absent, with the proviso that both  are not present at the same time; wherein when G is Q, R5 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, carboxyl, ester, and cyano and R6 is chosen from hydrocarbyl, substituted hydrocarbyl, carboxyl, ester, and cyano, with the proviso that when R6 is cyano, at least one of R7, R8, R10, and R11 is not a hydrogen.

PATENT INFORMATION


Interested in this Technology?

The technologies listed here are available for licensing or for developmental partnership.
Please contact us if you have any questions, or if you would like further information on these or other upcoming BioVentures technologies.

Contact